Athersys Initiates Patient Dosing in Phase I Acute Myocardial Infarction Study
Posted on: Thursday, 16 October 2008, 09:00 CDT
Athersys, a biopharmaceutical company, has initiated patient dosing of MultiStem in its ongoing Phase I clinical trial for individuals following acute myocardial infarction. The company has said that the MultiStem was delivered safely and tolerated well by the patient following administration.
The Phase I clinical trial is an open label, multi-center dose escalation trial evaluating the safety and maximum tolerated dose of single dose administration of allogeneic MultiStem following an acute myocardial infarction (AMI).
Following standard treatment, enrolled patients receive MultiStem delivered via a Cricket micro-infusion catheter, a proprietary device developed and manufactured by Mercator Medsystems of San Leandro, California.
Athersys has evaluated the safety and ability of MultiStem to improve heart function in multiple animal models, including well-validated preclinical models of AMI. Based on this preclinical work, the company believes that MultiStem may be administered safely and has the potential to improve heart function in patients following severe heart attacks. Athersys is jointly developing MultiStem for AMI with Angiotech Pharmaceuticals.
William Lehmann, president and COO of Athersys, said: "We are excited about the potential of MultiStem to provide benefit in multiple diseases and conditions, and we look forward to providing additional information about this Phase I clinical trial and other studies as we move our programs ahead."
Source: Datamonitor
Related Articles
- American Heart Association Late Breaking Clinical Trial Report: High Dose of Angiotensin Receptor Blockers Effective in Heart Failure Patients
- RhuDex(R) Achieves Positive Results in Clinical Phase IIa Trial
- KaloBios Completes Patient Dosing in Its U.S. Phase 1 Trial of Its Third Drug Candidate, KB003
- Next Generation Nasal Spray Against Influenza: Clinical Phase I Study Started With FLUVACCdelNS1
- Ambit Biosciences Begins Dosing Patients in Phase I Clinical Trial of Lead Kinase Inhibitor AC220
- Pharmos Commences Dosing in Second Phase 2a Study of Cannabinor in Experimentally Induced Pain
- Concern Over Heart Devices Hindering National Study: Only One Patient From Heart Clinic Willing to Enroll in Experiment
- St. Paul Heart Clinic Seeks Heart Failure Patients for Investigational Study Evaluating Use of New Implantable Pulse Generator
- Amarin Reports Initiation of Enrollment and First Patient Dosing in Pivotal Phase III Clinical Trials for Miraxion in Huntington's Disease
- Clinical Trial Links Celebrex to Heart Risk
 |
 |
User Comments (0)
RSS Feeds